Spots Global Cancer Trial Database for sargramostim
Every month we try and update this database with for sargramostim cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma | NCT00256282 | Metastatic Mela... | Vinorelbine Docetaxel Sargramostim | 18 Years - | University of California, Irvine | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI | NCT00363649 | Leukemia | GM-K562 cell va... Interferon alfa Sargramostim | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Combination Chemotherapy in Treating Children With Neuroblastoma | NCT00003093 | Neuroblastoma | filgrastim sargramostim carboplatin cyclophosphamid... doxorubicin hyd... etoposide conventional su... neoadjuvant the... | - 20 Years | Children's Oncology Group | |
| Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | NCT00546377 | Leukemia Lymphoma | filgrastim pegfilgrastim rituximab sargramostim cyclophosphamid... mitoxantrone hy... pentostatin fluorescence in... gene rearrangem... polymerase chai... protein express... flow cytometry biopsy | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia | NCT00003003 | Leukemia | sargramostim mitomycin C mitoxantrone hy... | 18 Years - 120 Years | Dartmouth-Hitchcock Medical Center | |
| Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma | NCT00005987 | Multiple Myelom... | carmustine cyclophosphamid... dexamethasone etoposide filgrastim mitoxantrone hy... recombinant int... sargramostim bone marrow abl... peripheral bloo... radiation thera... | - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | NCT00003222 | Melanoma (Skin) | aldesleukin gp100 antigen incomplete Freu... sargramostim tetanus peptide... tyrosinase pept... | 18 Years - 79 Years | University of Virginia | |
| A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer | NCT05242965 | Lung Non-Small ... Stage IV Lung C... | CD105/Yb-1/SOX2... Sargramostim Computed Tomogr... Biopsy Biospecimen Col... | 18 Years - | University of Washington | |
| GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer | NCT00262808 | Colorectal Canc... | sargramostim fluorouracil leucovorin calc... oxaliplatin adjuvant therap... conventional su... neoadjuvant the... | 18 Years - | University of Rochester | |
| Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | NCT00005601 | Lymphoma | rituximab cisplatin cytarabine dexamethasone sargramostim | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Ketoconazole, Hydrocortisone, and GM-CSF in Treating Patients With Progressive Prostate Cancer After Hormone Therapy | NCT00309894 | Prostate Cancer | sargramostim ketoconazole therapeutic hyd... | - 120 Years | University of California, San Francisco | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00053131 | Leukemia | filgrastim sargramostim cytarabine mitoxantrone hy... | 15 Years - | Roswell Park Cancer Institute | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma | NCT02484443 | Metastatic Mali... Metastatic Oste... Recurrent Osteo... | Dinutuximab Laboratory Biom... Pharmacological... Sargramostim | - 29 Years | National Cancer Institute (NCI) | |
| S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00040937 | Multiple Myelom... | filgrastim sargramostim cyclophosphamid... dexamethasone melphalan prednisone thalidomide peripheral bloo... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | NCT00066794 | Leukemia | filgrastim sargramostim cyclosporine cytarabine daunorubicin hy... | 56 Years - | SWOG Cancer Research Network | |
| Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma | NCT00008008 | Brain and Centr... | filgrastim sargramostim cyclophosphamid... thiotepa autologous bone... bone marrow abl... peripheral bloo... | - | National Cancer Institute (NCI) | |
| Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers | NCT00003163 | Lymphoma Multiple Myelom... | filgrastim sargramostim cyclophosphamid... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00266110 | Breast Cancer | sargramostim therapeutic aut... trastuzumab vinorelbine dit... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00004217 | Leukemia | filgrastim sargramostim cytarabine daunorubicin hy... valspodar | 56 Years - | SWOG Cancer Research Network | |
| Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent | NCT02470559 | Malignant Ovari... Malignant Ovari... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... Stage IIIA Fall... Stage IIIA Ovar... Stage IIIA Prim... Stage IIIB Fall... Stage IIIB Ovar... Stage IIIB Prim... Stage IIIC Fall... Stage IIIC Ovar... Stage IIIC Prim... Stage IV Fallop... Stage IV Ovaria... Stage IV Primar... | Aldesleukin HER2Bi-Armed Ac... Laboratory Biom... Sargramostim | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma | NCT00002697 | Lymphoma | filgrastim sargramostim carboplatin etoposide ifosfamide autologous bone... bone marrow abl... peripheral bloo... radiation thera... | 18 Years - 65 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer | NCT00022230 | Breast Cancer | aldesleukin filgrastim sargramostim therapeutic aut... cyclophosphamid... doxorubicin hyd... paclitaxel | 18 Years - | Roger Williams Medical Center | |
| Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma | NCT00004184 | Melanoma (Skin) | monoclonal anti... sargramostim alum adjuvant | 18 Years - | University of Alabama at Birmingham | |
| Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma | NCT00308087 | Lymphoma, Folli... | Sargramostim (L... Rituximab | 18 Years - | Sanofi | |
| Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | NCT00069940 | Brain and Centr... Gastrointestina... Sarcoma | sargramostim telomerase: 540... | 2 Years - | Dana-Farber Cancer Institute | |
| Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer | NCT00079157 | Breast Cancer | incomplete Freu... sargramostim telomerase: 540... | 18 Years - 120 Years | Abramson Cancer Center at Penn Medicine | |
| HER2-Peptide Vaccination of Patients With Solid Tumors | NCT02276300 | Gastric Cancer Breast Cancer | Cyclophosphamid... Sargramostim HER2-Peptid-Vak... Imiquimod | 18 Years - | Technical University of Munich | |
| Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer | NCT00002475 | Breast Cancer Colorectal Canc... Kidney Cancer Lung Cancer Malignant Mesot... Pancreatic Canc... | allogeneic tumo... autologous tumo... recombinant int... recombinant int... sargramostim cyclophosphamid... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma | NCT00089193 | Melanoma (Skin) | incomplete Freu... multi-epitope m... sargramostim | 12 Years - | University of Virginia | |
| Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | NCT02873819 | Squamous Cell C... | GL-0817 Hiltonol Sargramostim cyclophosphamid... Placebo | 18 Years - | Gliknik Inc. | |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia | NCT00002638 | Leukemia | filgrastim sargramostim carmustine cyclophosphamid... cytarabine etoposide peripheral bloo... radiation thera... | 1 Year - 19 Years | National Cancer Institute (NCI) | |
| Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis | NCT00007995 | Multiple Myelom... | filgrastim recombinant int... sargramostim busulfan cyclophosphamid... melphalan autologous bone... bone marrow abl... peripheral bloo... | 18 Years - | National Cancer Institute (NCI) | |
| Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer | NCT00004256 | Head and Neck C... Oral Complicati... Radiation Toxic... | sargramostim quality-of-life... radiation thera... | 20 Years - 80 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | NCT00398138 | Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton... | WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te... | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy | NCT00673179 | Osteosarcoma | Doxorubicin Cisplatin Methotrexate Leucovorin Dexrazoxane Ifosfamide Questionnaire Gemcitabine Sargramostim Surgery Mesna | 5 Years - 40 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery | NCT00652860 | Metastatic Canc... Sarcoma | aerosol sargram... sargramostim cisplatin doxorubicin hyd... ifosfamide mitomycin C flow cytometry immunological d... laboratory biom... adjuvant therap... multimodality t... neoadjuvant the... therapeutic con... intraoperative ... selective exter... | 18 Years - | Mayo Clinic | |
| Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | NCT02593123 | Hodgkin's Lymph... Lymphoid Leukem... Lymphoma Leukemia Myeloma Acute Lymphocyt... Non Hodgkin Lym... Chronic Lymphoc... Multiple Myelom... Chronic Myeloge... Myelodysplastic... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Recurrent Plasm... Recurrent Chron... Recurrent Chron... Acute Myelogeno... | mycophenolate m... Sargramostim Filgrastim | 18 Years - 74 Years | Virginia Commonwealth University | |
| Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS | NCT01700673 | Acute Myeloid L... Myelodysplastic... | Azacitidine Sargramostim | 6 Months - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | NCT00003397 | Lymphoma | filgrastim rituximab sargramostim carmustine cisplatin cyclophosphamid... dexamethasone etoposide gemcitabine hyd... melphalan paclitaxel bone marrow abl... peripheral bloo... | 18 Years - 75 Years | University of Maryland, Baltimore | |
| Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors | NCT00003125 | Breast Cancer Esophageal Canc... Gastric Cancer Lung Cancer Pancreatic Canc... Unspecified Adu... | ALVAC-CEA vacci... aldesleukin sargramostim vaccinia-CEA va... | 18 Years - | Georgetown University | |
| Vaccine Therapy and Sargramostim in Treating Patients With Non-small Cell Lung Cancer | NCT00005630 | Lung Cancer | ras peptide can... sargramostim | 17 Years - | Memorial Sloan Kettering Cancer Center | |
| Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | NCT01826864 | Stage IB Melano... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... | sargramostim sentinel lymph ... laboratory biom... hypertonic sali... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | NCT03786783 | Ganglioneurobla... High Risk Neuro... | Autologous Hema... Carboplatin Cisplatin Cyclophosphamid... Dexrazoxane Dinutuximab Doxorubicin Etoposide External Beam R... Isotretinoin Melphalan Sargramostim Thiotepa Topotecan Vincristine | - 30 Years | National Cancer Institute (NCI) | |
| Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia | NCT00446173 | Leukemia | Busulfan Cyclophosphamid... G-CSF GM-CSF | 21 Years - 65 Years | M.D. Anderson Cancer Center | |
| Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer | NCT00003181 | Kidney Cancer | aldesleukin sargramostim vinblastine sul... | 18 Years - | National Cancer Institute (NCI) | |
| Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma | NCT00450307 | Neuroblastoma | monoclonal anti... sargramostim | - 21 Years | Memorial Sloan Kettering Cancer Center | |
| p53 Vaccine for Ovarian Cancer | NCT00001827 | Ovarian Neoplas... | aldesleukin incomplete Freu... p53 peptide vac... sargramostim therapeutic aut... in vitro-treate... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma | NCT00026312 | Localized Resec... Localized Unres... Recurrent Neuro... Regional Neurob... Stage 4 Neurobl... Stage 4S Neurob... | Aldesleukin Dinutuximab Isotretinoin Laboratory Biom... Pharmacological... Quality-of-Life... Sargramostim | - 30 Years | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma | NCT00002817 | Melanoma (Skin) | sargramostim vaccinia-GM-CSF... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia | NCT00466726 | Leukemia | bcr-abl p210-b3... sargramostim | 18 Years - 120 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | NCT00012246 | Colorectal Canc... Esophageal Canc... Extrahepatic Bi... Gallbladder Can... Gastric Cancer Pancreatic Canc... Small Intestine... | carcinoembryoni... incomplete Freu... sargramostim | 18 Years - | The University of Texas Medical Branch, Galveston | |
| Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma | NCT01826864 | Stage IB Melano... Stage IIA Melan... Stage IIB Melan... Stage IIC Melan... | sargramostim sentinel lymph ... laboratory biom... hypertonic sali... | 18 Years - 75 Years | Jonsson Comprehensive Cancer Center | |
| Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery | NCT00278122 | Melanoma (Skin) | sargramostim paclitaxel | 18 Years - | University of Virginia | |
| Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT00643097 | Malignant Neopl... | PEP-3 vaccine sargramostim Temozolomide | 18 Years - | Duke University | |
| High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML) | NCT00050531 | Leukemia, Myelo... | Gleevec Peg-alpha inter... Sargramostim (G... | 18 Years - | M.D. Anderson Cancer Center | |
| FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | NCT00381004 | Chronic Lymphoc... | Cyclophosphamid... Fludarabine Sargramostim Rituximab | - | M.D. Anderson Cancer Center | |
| Phase I Trial of mBACOD and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in AIDS-Associated Large Cell, Immunoblastic, and Small Non-cleaved Lymphoma | NCT00000689 | Lymphoma, Non-H... HIV Infections | Bleomycin sulfa... Vincristine sul... Doxorubicin hyd... Cyclophosphamid... Methotrexate Cytarabine Leucovorin calc... Sargramostim Dexamethasone | 13 Years - | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Vaccine Therapy in Treating Women With Metastatic Breast Cancer | NCT00003184 | Breast Cancer | BCG vaccine CD80 breast can... sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer | NCT00400517 | Prostate Cancer | sargramostim thalidomide conventional su... neoadjuvant the... | - 120 Years | The Cleveland Clinic | |
| GM-CSF Before Surgery in Treating Patients With Localized Prostate Cancer | NCT00305669 | Prostate Cancer | sargramostim immunohistochem... immunological d... laboratory biom... conventional su... neoadjuvant the... | - | University of California, San Francisco | |
| UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma | NCT04382664 | Malignant Melan... | UV1 Sargramostim Ipilimumab Nivolumab | 18 Years - | Ultimovacs ASA | |
| Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer | NCT00019084 | Breast Cancer Cervical Cancer Colorectal Canc... Lung Cancer Ovarian Cancer Pancreatic Canc... | aldesleukin mutant p53 pept... ras peptide can... sargramostim therapeutic aut... therapeutic tum... | 18 Years - | National Cancer Institute (NCI) | |
| Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung | NCT00006483 | Kidney Cancer Metastatic Canc... | sargramostim | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome | NCT00003959 | Leukemia Myelodysplastic... | ras peptide can... sargramostim | 17 Years - | Memorial Sloan Kettering Cancer Center | |
| Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer | NCT00899821 | Head and Neck C... | aldesleukin recombinant int... sargramostim immunologic tec... biopsy | 20 Years - 80 Years | NYU Langone Health | |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma | NCT00006385 | Melanoma (Skin) | MART-1 antigen gp100 antigen incomplete Freu... recombinant int... sargramostim tyrosinase pept... | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | NCT00020254 | Prostate Cancer | aldesleukin recombinant fow... recombinant vac... recombinant vac... sargramostim nilutamide | 18 Years - | National Cancer Institute (NCI) | |
| Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT01222221 | Brain and Centr... | glioblastoma mu... sargramostim temozolomide laboratory biom... pharmacological... adjuvant therap... radiation thera... | 18 Years - | Cancer Research UK | |
| Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma | NCT00258336 | Lymphoma | autologous immu... rituximab sargramostim | 18 Years - | National Cancer Institute (NCI) | |
| GM-CSF in Treating Patients With Relapsed Prostate Cancer | NCT00908141 | Prostate Cancer | sargramostim | 18 Years - | Case Comprehensive Cancer Center | |
| Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT00006240 | Leukemia | sargramostim dexamethasone oral sodium phe... | 18 Years - | National Cancer Institute (NCI) | |
| Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma | NCT00066365 | Metastatic Canc... Sarcoma | sargramostim conventional su... | - 39 Years | Children's Oncology Group | |
| GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer | NCT00293462 | Head and Neck C... Mucositis Oral Radiation Toxic... Tongue Cancer | sargramostim oral salt and s... | 18 Years - | University of California, San Francisco | |
| Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment | NCT00089258 | Neuroblastoma | beta-glucan monoclonal anti... sargramostim isotretinoin | - | Memorial Sloan Kettering Cancer Center | |
| Samarium Sm 153 Lexidronam Pentasodium and High-Dose Melphalan in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | NCT00602706 | Multiple Myelom... | sargramostim melphalan autologous hema... peripheral bloo... samarium Sm 153... | 18 Years - | Mayo Clinic | |
| GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma | NCT00896519 | Lymphoma | rituximab sargramostim cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... gene expression... gene rearrangem... polymerase chai... R-CHOP regimen laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma | NCT00006669 | Lymphoma | rituximab sargramostim EPOCH regimen cyclophosphamid... doxorubicin hyd... etoposide prednisone vincristine sul... | 18 Years - 120 Years | Medstar Health Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
